Swedish Orphan Biovitrum AB (publ) (BIT:1SOBI)

Market Cap	8.71B
Revenue (ttm)	2.27B
Net Income (ttm)	339.06M
Shares Out	n/a
EPS (ttm)	0.98
PE Ratio	25.69
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	n/a
Previous Close	23.48
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
RSI	45.22
Earnings Date	Mar 31, 2025

About BIT:1SOBI

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology and Specialty Care. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for hae...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,806
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1SOBI

Financial Performance

In 2024, BIT:1SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK